CordenPharma Expands Aseptic Filling Capacity to 500 Million Sterile Injectable Units Annually
CordenPharma, a leading Contract Development and Manufacturing Organization (CDMO) specializing in complex pharmaceuticals, is making significant strides in expanding its capacity for aseptic filling and packaging of sterile injectables. In a recent announcement dated September 10, 2026, the company revealed a multi-year investment of €80 million aimed at enhancing its capabilities at its FDA and EMA-approved facility located in Caponago, Italy. This expansion represents a pivotal move to solidify CordenPharma's leadership in the global sterile injectable market, with an ambitious target of reaching a production capacity of 500 million sterile injectable units annually.
The core of this expansion initiative lies in the acquisition of a new commercial building measuring 11,000 m² and a 26,000 m² plot near its existing aseptic filling and packaging area. This strategic acquisition, valued at €13 million, was completed on July 28, 2026, marking a key milestone in the company’s growth strategy. The site’s footprint will increase by over 50%, providing ample space for the installation of advanced production lines tailored to meet the growing demands of pharmaceutical innovators.
The new facility is designed to offer bespoke contract manufacturing services for a diverse range of therapeutic injectable products, including those involving peptides, nucleic acid products (NPL), small molecules, biological products, and oligonucleotides. CordenPharma’s expanded capabilities will support multiple product formats, such as prefilled syringes (PFS), vials (both liquid and lyophilized), cartridges, and auto-injectors, ensuring clients receive comprehensive and streamlined solutions under one roof.
CordenPharma has outlined plans to incorporate at least four additional aseptic filling and packaging lines, augmenting its current production infrastructure. This includes the installation of advanced isolator lines aimed at enhancing the integrity and sterility assurance of injectable products. One line, specifically designed for clinical and small-scale commercial production, will facilitate the filling of prefilled syringes, vials, and cartridges. Another high-speed line will be capable of producing over 500,000 PFS and cartridge units daily.
Moreover, the initiative will also double the company’s analytical capacity to support its expanding project portfolio effectively. The anticipated completion dates for the new isolator lines are set for mid-2027 and 2028, which will ensure compliance with stringent sterility standards in the manufacture of sterile injectables.
The escalation of production capacity reflects CordenPharma’s proactive strategy to address the surging global demand for specialized injectable manufacturing. Therapeutic areas such as oncology, obesity, diabetes, and inflammatory diseases particularly rely on complex administration modalities, including GLP-1 peptide therapies, oligonucleotides, and biosimilars. This enhanced capability will allow CordenPharma to meet the needs of its clients across a range of therapeutic domains, ultimately benefiting patient care by ensuring the availability of essential medications.
CordenPharma's investment highlights its commitment to advancing its production facilities and capabilities in response to the growing trend of outsourcing sterile injectable manufacturing. With a robust portfolio, the company can support innovators throughout the lifecycle of their injectable products, from early-phase projects to large-scale commercial production.
Dr. Michael Quirmbach, CEO of CordenPharma, emphasized the significance of this investment, stating, “The backing from our shareholder, Astorg, underlines our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. This strategic investment reinforces our position as a leader in complex pharmaceuticals and enhances our end-to-end supply capabilities to meet the escalating worldwide demand for outsourcing injectable products.”
In conclusion, CordenPharma is poised for substantial growth in the realm of sterile injectables, bolstered by its significant capital investments and expansions in operational capacities. As the company continues to innovate and adapt to market needs, it remains dedicated to providing comprehensive, high-quality solutions that empower pharmaceutical clients in bringing life-saving therapies to market efficiently and reliably. For further information, visit CordenPharma’s official website at cordenpharma.com.
Strategic Expansion
The core of this expansion initiative lies in the acquisition of a new commercial building measuring 11,000 m² and a 26,000 m² plot near its existing aseptic filling and packaging area. This strategic acquisition, valued at €13 million, was completed on July 28, 2026, marking a key milestone in the company’s growth strategy. The site’s footprint will increase by over 50%, providing ample space for the installation of advanced production lines tailored to meet the growing demands of pharmaceutical innovators.
The new facility is designed to offer bespoke contract manufacturing services for a diverse range of therapeutic injectable products, including those involving peptides, nucleic acid products (NPL), small molecules, biological products, and oligonucleotides. CordenPharma’s expanded capabilities will support multiple product formats, such as prefilled syringes (PFS), vials (both liquid and lyophilized), cartridges, and auto-injectors, ensuring clients receive comprehensive and streamlined solutions under one roof.
Enhanced Aseptic Production Lines
CordenPharma has outlined plans to incorporate at least four additional aseptic filling and packaging lines, augmenting its current production infrastructure. This includes the installation of advanced isolator lines aimed at enhancing the integrity and sterility assurance of injectable products. One line, specifically designed for clinical and small-scale commercial production, will facilitate the filling of prefilled syringes, vials, and cartridges. Another high-speed line will be capable of producing over 500,000 PFS and cartridge units daily.
Moreover, the initiative will also double the company’s analytical capacity to support its expanding project portfolio effectively. The anticipated completion dates for the new isolator lines are set for mid-2027 and 2028, which will ensure compliance with stringent sterility standards in the manufacture of sterile injectables.
Meeting Global Demand
The escalation of production capacity reflects CordenPharma’s proactive strategy to address the surging global demand for specialized injectable manufacturing. Therapeutic areas such as oncology, obesity, diabetes, and inflammatory diseases particularly rely on complex administration modalities, including GLP-1 peptide therapies, oligonucleotides, and biosimilars. This enhanced capability will allow CordenPharma to meet the needs of its clients across a range of therapeutic domains, ultimately benefiting patient care by ensuring the availability of essential medications.
CordenPharma's investment highlights its commitment to advancing its production facilities and capabilities in response to the growing trend of outsourcing sterile injectable manufacturing. With a robust portfolio, the company can support innovators throughout the lifecycle of their injectable products, from early-phase projects to large-scale commercial production.
Dr. Michael Quirmbach, CEO of CordenPharma, emphasized the significance of this investment, stating, “The backing from our shareholder, Astorg, underlines our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. This strategic investment reinforces our position as a leader in complex pharmaceuticals and enhances our end-to-end supply capabilities to meet the escalating worldwide demand for outsourcing injectable products.”
Conclusion
In conclusion, CordenPharma is poised for substantial growth in the realm of sterile injectables, bolstered by its significant capital investments and expansions in operational capacities. As the company continues to innovate and adapt to market needs, it remains dedicated to providing comprehensive, high-quality solutions that empower pharmaceutical clients in bringing life-saving therapies to market efficiently and reliably. For further information, visit CordenPharma’s official website at cordenpharma.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.